IO Biotech, Inc. (NASDAQ:IOBT - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for IO Biotech in a research note issued on Tuesday, April 1st. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.50) for the quarter. HC Wainwright currently has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for IO Biotech's current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for IO Biotech's Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.42) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.91) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.39) EPS, FY2028 earnings at ($0.39) EPS, FY2029 earnings at ($0.13) EPS and FY2029 earnings at ($0.13) EPS.
Separately, Piper Sandler raised IO Biotech to a "strong-buy" rating in a research report on Wednesday, March 12th.
Read Our Latest Analysis on IOBT
IO Biotech Stock Performance
IOBT stock traded up $0.02 during trading on Friday, hitting $0.86. 123,883 shares of the company's stock traded hands, compared to its average volume of 272,229. The stock has a market capitalization of $56.33 million, a price-to-earnings ratio of -0.62 and a beta of 0.08. IO Biotech has a 52 week low of $0.66 and a 52 week high of $1.79. The business has a fifty day simple moving average of $0.96 and a 200 day simple moving average of $0.97.
Institutional Investors Weigh In On IO Biotech
A number of institutional investors and hedge funds have recently added to or reduced their stakes in IOBT. XTX Topco Ltd bought a new stake in shares of IO Biotech during the fourth quarter valued at approximately $26,000. Vontobel Holding Ltd. purchased a new position in IO Biotech during the 4th quarter worth $30,000. Renaissance Technologies LLC raised its position in IO Biotech by 22.5% during the 4th quarter. Renaissance Technologies LLC now owns 118,800 shares of the company's stock valued at $109,000 after purchasing an additional 21,800 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of IO Biotech in the 4th quarter worth $249,000. Finally, Landscape Capital Management L.L.C. bought a new position in shares of IO Biotech during the 4th quarter worth $407,000. Institutional investors own 54.76% of the company's stock.
About IO Biotech
(
Get Free Report)
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
Featured Stories
Before you consider IO Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IO Biotech wasn't on the list.
While IO Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
